From October 15 to 16, 2018, the partners of HypoSens, among which is bcb, will have their 24-month meeting in Logroño (Spain), organized by the Center for Biomedical Research of La Rioja CEBIR, one of the Spanish partners of the draft. The first prototype of the device will be installed and the first months will be the first clinical and preclinical validations in the CEBIR of Fundación Rioja Salud, once the device is adjusted by Technion, Albanian University and bcb, the partners responsible for the implementation, development and optimization of the optical device.
Also this October, the European HypoSens project will be present at the Healthio event in Barcelona.
bcb is one of the partners of this interesting project, which focuses on the development, clinical and preclinical validations and the industrial demonstration of a unique system of totally optical cancer prognosis. The project is now in its 24 Month, with the status of implementation of the project shown on the poster.
